ImmuPharma plc

ImmuPharma plc, established in London, United Kingdom, in 1999, is a biopharmaceutical company dedicated to discovering and advancing peptide-based therapeutics. These treatments are focused on tackling conditions related to autoimmunity, inflammation, and various infections. The company's primary drug candidate, Lupuzor, an autophagy immunomodulator, is presently in Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disorder. Additional product developments include BioAMB, a peptide-based medication for fungal infections, particularly those caused by the aspergillus family, and BioCin, a peptide-derived antibacterial agent designated for high medical need and as a last-resort treatment option. ImmuPharma also maintains a partnership with the Centre National de la Recherche Scientifique (CNRS) to develop a peptide technology platform aimed at diabetes, specifically involving GLP-1 agonists and glucagon antagonists for both Type I and Type II diabetes. Furthermore, the company has a licensing and development agreement in place with Avion Pharmaceuticals LLC.